ConductScience.org, home

Comparison · NCT04180462-ea748996

Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. Trial comparisons, record NCT04180462-ea748996. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04180462-ea748996

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.820.8030.835wilson
Risk in group 20.7460.7230.768wilson
Risk difference, group 1 minus group 20.07340.04590.101newcombe hybrid score
Risk ratio, group 1 over group 21.11.061.14log
Odds ratio, group 1 over group 21.551.311.82log
Number needed to treat, for one more participant with the outcome on Intervention Group than on Wait List Control Group13.69.8621.8from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Intervention GroupPractices randomly assigned to this arm will receive the multi-component intervention.1,8122,211OG000
Group 2Wait List Control GroupPractices randomly assigned to this arm will be offered the intervention in the last two years of the study.1,0521,410OG001

Outcome

Type
SECONDARY
Title
Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine.
Description
The proportion of eligible preteens who receive the 1st dose of HPV vaccine before their 13th birthday at 36 months, post randomization
Time frame
36 months
Population

Source ClinicalTrials.gov

Trial

Title
Increasing Optimal Use of HPV Vaccination in Primary Care
NCT number
NCT04180462
Phases
NA
Conditions
Human Papillomavirus Vaccines
Interventions
Practice Facilitation, Education, Audit and Feedback, Communication Strategy
Lead sponsor
Washington University School of Medicine
Results first posted
2024-02-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04180462-ea748996